KR930004325A - 3-데옥시-만노사민 유도체 및 이의 제조방법. - Google Patents
3-데옥시-만노사민 유도체 및 이의 제조방법. Download PDFInfo
- Publication number
- KR930004325A KR930004325A KR1019920013968A KR920013968A KR930004325A KR 930004325 A KR930004325 A KR 930004325A KR 1019920013968 A KR1019920013968 A KR 1019920013968A KR 920013968 A KR920013968 A KR 920013968A KR 930004325 A KR930004325 A KR 930004325A
- Authority
- KR
- South Korea
- Prior art keywords
- dideoxy
- mannopyranose
- compound
- acetamido
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SNDZDGQLFKEBLF-NSHGFSBMSA-N (3s,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,5-diol Chemical class N[C@H]1C[C@H](O)[C@@H](CO)OC1O SNDZDGQLFKEBLF-NSHGFSBMSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 10
- 239000011737 fluorine Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 3
- UCDQAXYQHZEAED-KEWYIRBNSA-N n-[(3r,4r,5r,6r)-4-fluoro-2,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1F UCDQAXYQHZEAED-KEWYIRBNSA-N 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- FUJCLTYQZPQJJG-GASJEMHNSA-N (3r,4r,5r,6r)-3-amino-4-fluoro-6-(hydroxymethyl)oxane-2,5-diol Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1F FUJCLTYQZPQJJG-GASJEMHNSA-N 0.000 claims 2
- PPLYUQFILYXJFE-GASJEMHNSA-N (3r,4r,5r,6r)-3-amino-6-(hydroxymethyl)-4-iodooxane-2,5-diol Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1I PPLYUQFILYXJFE-GASJEMHNSA-N 0.000 claims 2
- ZRAGVAZPJFCAOQ-SOOFDHNKSA-N (3r,5r,6r)-3-amino-4,4-difluoro-6-(hydroxymethyl)oxane-2,5-diol Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)C1(F)F ZRAGVAZPJFCAOQ-SOOFDHNKSA-N 0.000 claims 2
- BAXLINYAWKNTSZ-WZPXOXCRSA-N (3s,4r,5s,6r)-3-amino-4-ethyl-6-(hydroxymethyl)oxane-2,5-diol Chemical compound CC[C@@H]1[C@H](N)C(O)O[C@H](CO)[C@H]1O BAXLINYAWKNTSZ-WZPXOXCRSA-N 0.000 claims 2
- BKTLDUOWUNMFOU-BWSJPXOBSA-N (3s,4r,5s,6r)-3-amino-6-(hydroxymethyl)-4-methyloxane-2,5-diol Chemical compound C[C@@H]1[C@H](N)C(O)O[C@H](CO)[C@H]1O BKTLDUOWUNMFOU-BWSJPXOBSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- LQLVEPRLISPUBJ-KEWYIRBNSA-N n-[(3r,4r,5r,6r)-2,5-dihydroxy-6-(hydroxymethyl)-4-iodooxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1I LQLVEPRLISPUBJ-KEWYIRBNSA-N 0.000 claims 2
- PKBIKUMIANJDIJ-LCJYRESISA-N n-[(3s,4r,5s,6r)-2,5-dihydroxy-6-(hydroxymethyl)-4-methyloxan-3-yl]acetamide Chemical compound C[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1NC(C)=O PKBIKUMIANJDIJ-LCJYRESISA-N 0.000 claims 2
- TXCXTHVUFAXSSL-QBARFFCXSA-N n-[(3s,5s,6r)-2,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@H]1C[C@H](O)[C@@H](CO)OC1O TXCXTHVUFAXSSL-QBARFFCXSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- WEGAZRQPNJDIJL-RYRJNEICSA-N (3s,4r,5s,6r)-3-amino-6-(hydroxymethyl)-4-methoxyoxane-2,5-diol Chemical compound CO[C@@H]1[C@H](N)C(O)O[C@H](CO)[C@H]1O WEGAZRQPNJDIJL-RYRJNEICSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- QIUQFQKHOBPZEF-NTUKYRGVSA-N n-[(3s,4r,5s,6r)-4-ethyl-2,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1NC(C)=O QIUQFQKHOBPZEF-NTUKYRGVSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919116896A GB9116896D0 (en) | 1991-08-06 | 1991-08-06 | 3-deoxymannosamine derivatives and process for their preparation |
| GB9116896.6 | 1991-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930004325A true KR930004325A (ko) | 1993-03-22 |
Family
ID=10699545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920013968A Withdrawn KR930004325A (ko) | 1991-08-06 | 1992-08-04 | 3-데옥시-만노사민 유도체 및 이의 제조방법. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5332756A (enExample) |
| EP (1) | EP0527042A2 (enExample) |
| JP (1) | JPH05208988A (enExample) |
| KR (1) | KR930004325A (enExample) |
| AU (1) | AU646173B2 (enExample) |
| CA (1) | CA2075336A1 (enExample) |
| FI (1) | FI923498L (enExample) |
| GB (1) | GB9116896D0 (enExample) |
| HU (1) | HU213208B (enExample) |
| IL (1) | IL102500A (enExample) |
| MX (1) | MX9204395A (enExample) |
| MY (1) | MY108749A (enExample) |
| NZ (1) | NZ243627A (enExample) |
| RU (1) | RU2099333C1 (enExample) |
| TW (1) | TW248564B (enExample) |
| ZA (1) | ZA925871B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9216962D0 (en) * | 1992-08-11 | 1992-09-23 | Erba Carlo Spa | Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives |
| GB9304589D0 (en) * | 1993-03-05 | 1993-04-21 | Erba Carlo Spa | Biologically active ureido derivatives useful as antimetastic agents |
| FR2723947B1 (fr) * | 1994-08-31 | 1996-09-27 | Adir | Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| RU2266734C2 (ru) * | 1999-05-13 | 2005-12-27 | Фарма Мар, С.А. | Композиции и применение ет743 для лечения злокачественных опухолей |
| JP4943839B2 (ja) * | 2004-05-26 | 2012-05-30 | 株式会社希少糖生産技術研究所 | 血管新生抑制剤 |
| US8148335B2 (en) | 2004-06-23 | 2012-04-03 | Children's Hospital & Research Center Oakland | De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy |
| WO2006002402A2 (en) * | 2004-06-23 | 2006-01-05 | Children's Hospital & Research Center At Oakland | Polysaccharide derivatives and uses in induction of an immune response |
| US20090214439A1 (en) * | 2006-03-15 | 2009-08-27 | Trustees Of Tufts College | Fluorinated Carbohydrates and Their Use in Tumor Visualization, Tissue Engineering, and Cancer Chemotherapy |
| KR100780868B1 (ko) | 2006-07-10 | 2007-11-30 | 부경대학교 산학협력단 | 항암효과를 나타내는 4급 아미노 글루코사민 화합물 |
| US8999954B2 (en) * | 2007-07-03 | 2015-04-07 | Childern's Hospital & Research Center at Oakland | Inhibitors of polysialic acid de-N-acetylase and methods for using the same |
| JP5523313B2 (ja) | 2007-07-03 | 2014-06-18 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用 |
| JP5702600B2 (ja) * | 2007-07-03 | 2015-04-15 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | オリゴシアル酸誘導体、製造方法および免疫学的使用 |
| FR2930943B1 (fr) * | 2008-05-07 | 2011-03-18 | Centre Nat Rech Scient | Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4216208A (en) * | 1978-07-31 | 1980-08-05 | Proter S.P.A. | N-Acyl derivatives of glucosamines having antitumor chemotherapeutic activity |
| US4647453A (en) * | 1984-10-18 | 1987-03-03 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| DE3906174A1 (de) * | 1989-02-28 | 1990-08-30 | Forschungszentrum Juelich Gmbh | Verfahren zur herstellung von d-mannosaminderivaten |
-
1991
- 1991-08-06 GB GB919116896A patent/GB9116896D0/en active Pending
-
1992
- 1992-07-15 HU HU9202329A patent/HU213208B/hu not_active IP Right Cessation
- 1992-07-15 IL IL10250092A patent/IL102500A/en not_active IP Right Cessation
- 1992-07-17 AU AU20374/92A patent/AU646173B2/en not_active Ceased
- 1992-07-20 NZ NZ243627A patent/NZ243627A/xx unknown
- 1992-07-27 MX MX9204395A patent/MX9204395A/es unknown
- 1992-07-31 US US07/922,229 patent/US5332756A/en not_active Expired - Fee Related
- 1992-08-01 TW TW081106118A patent/TW248564B/zh active
- 1992-08-03 FI FI923498A patent/FI923498L/fi not_active Application Discontinuation
- 1992-08-04 MY MYPI92001390A patent/MY108749A/en unknown
- 1992-08-04 KR KR1019920013968A patent/KR930004325A/ko not_active Withdrawn
- 1992-08-05 JP JP4227760A patent/JPH05208988A/ja active Pending
- 1992-08-05 EP EP92307151A patent/EP0527042A2/en not_active Ceased
- 1992-08-05 RU SU925052492A patent/RU2099333C1/ru active
- 1992-08-05 CA CA002075336A patent/CA2075336A1/en not_active Abandoned
- 1992-08-05 ZA ZA925871A patent/ZA925871B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL102500A (en) | 1996-01-19 |
| ZA925871B (en) | 1993-04-28 |
| HU9202329D0 (en) | 1992-10-28 |
| EP0527042A3 (enExample) | 1994-01-05 |
| MX9204395A (es) | 1993-02-01 |
| FI923498A7 (fi) | 1993-02-07 |
| FI923498L (fi) | 1993-02-07 |
| RU2099333C1 (ru) | 1997-12-20 |
| HUT62593A (en) | 1993-05-28 |
| NZ243627A (en) | 1994-04-27 |
| EP0527042A2 (en) | 1993-02-10 |
| FI923498A0 (fi) | 1992-08-03 |
| CA2075336A1 (en) | 1993-02-07 |
| AU2037492A (en) | 1993-02-11 |
| GB9116896D0 (en) | 1991-09-18 |
| IL102500A0 (en) | 1993-01-14 |
| TW248564B (enExample) | 1995-06-01 |
| JPH05208988A (ja) | 1993-08-20 |
| MY108749A (en) | 1996-11-30 |
| AU646173B2 (en) | 1994-02-10 |
| US5332756A (en) | 1994-07-26 |
| HU213208B (en) | 1997-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930004325A (ko) | 3-데옥시-만노사민 유도체 및 이의 제조방법. | |
| ES8607721A1 (es) | Un procedimiento para la solubilizacion y estabilizacion de un agente antiparasitario. | |
| KR900006318A (ko) | 피페리디닐 벤즈이미다졸 | |
| KR890002060A (ko) | 옥사졸리디논 화합물 | |
| GB1360180A (en) | Anthelmintically active benzimidazole derivatives and process for preparing them | |
| KR890701563A (ko) | 화학적 방법 | |
| BG104640A (en) | Novel erythromycin derivatives | |
| KR900001677A (ko) | 비아릴 화합물 | |
| KR940701258A (ko) | 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도 | |
| KR910015562A (ko) | 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법 | |
| KR840007257A (ko) | 레베카마이신과 그것의 제조방법 | |
| JPS6468325A (en) | Antiviral compound | |
| KR910002802A (ko) | 1,2,3,4-테트라히드로-9-아크리딘아민의 유도체 | |
| KR910016915A (ko) | 과콜레스테롤혈증 치료제 | |
| KR870005004A (ko) | 마크롤라이드 항생물질 유도체 | |
| BE902876A (fr) | Derives d'aminophenol | |
| KR840005464A (ko) | 포스포리피드 유도체의 제조방법 | |
| KR890009962A (ko) | 매뉴마이신 유도체, 이의 제조방법 및 용도 | |
| KR950005306A (ko) | 매크롤라이드 및 그의 용도 | |
| KR920018215A (ko) | 류스트로덕신(leustroducsins)으로 명명된 신규 화합물, 그의 제조방법 및 그의 치료학적 용도 | |
| KR890005142A (ko) | 17-치환된 안드로스타-1,4-디엔-3-온 유도체 | |
| OA09022A (fr) | Nouveaux dérivés flavonoides pipérazyl-2 oxo-é éthylànes substitués, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| KR910016934A (ko) | 트립토판 동족체 공급에 의한 레베카마이신 동족체 | |
| DE3851362D1 (de) | Verfahren zur Herstellung von Cyclooctaamylose. | |
| KR900003177A (ko) | 테트라시클릭계 우울증 치료제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19920804 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |